Comparative Analysis of Analgesic Duration: Intrathecal Hyperbaric Levobupivacaine with Dexmedetomidine vs Morphine in Lower Segment Caesarean Sections
Authors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Background: Intrathecal adjuvants are commonly used to prolong postoperative analgesia following spinal anesthesia for caesarean section. Morphine is effective but associated with opioid-related adverse effects, while dexmedetomidine has emerged as a potential alternative. Aim: To compare the analgesic duration and safety profile of intrathecal hyperbaric levobupivacaine with morphine versus dexmedetomidine in parturients undergoing elective lower segment caesarean section. Material and Methods: A prospective randomized study involved 100 parturients divided into two groups. Group A received intrathecal hyperbaric levobupivacaine combined with 100 μg of morphine, with a mean age of 31.12 ± 4.08 years. Group B received intrathecal hyperbaric levobupivacaine with 3 μg of dexmedetomidine, with a mean age of 30.88 ± 4.32 years. Analgesic efficacy, hemodynamic parameters, adverse effects, and neonatal outcomes were assessed. Results: Both groups achieved adequate analgesia for 24 hours. Pain scores at 16 hours were significantly lower in the dexmedetomidine group. Opioid-related adverse effects were more frequent in the morphine group, while hemodynamic stability and neonatal outcomes were comparable. Conclusion: Intrathecal dexmedetomidine provides superior quality of analgesia with fewer adverse effects compared to morphine when used as an adjuvant to hyperbaric levobupivacaine for elective caesarean section.
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2026 Dr. Uday Pratap, Dr. Ruchi Gupta, Dr. Kishan Singh Kushawah
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.
[1] Landau R, Segal S, Yakobi R, Smiley RM, Carvalho B, Sultan P. Neuraxial anesthesia and pain management for cesarean delivery. Am J Obstet Gynecol. 2023;229(4):401–412.
[2] Borrelli MC, Sprowell AJ, Moldysz A, Smiley RM, Carvalho B, Sultan P. A randomized controlled trial of spinal morphine and duration of analgesia after cesarean delivery. Anaesth Crit Care Pain Med. 2024;43(1):101309.
[3] Carvalho B, Sultan P, Riley ET. Neuraxial opioids in obstetric anesthesia. Anesth Analg. 2022;134(5):1011–1024.
[4] Renard Y, El-Boghdadly K, Rossel JB, Albrecht E, Richebé P, Tran DQ. Non-pulmonary complications of intrathecal morphine: A systematic review. Br J Anaesth. 2024;133(4):823–838.
[5] Mo X, Li Y, Zhang J, Wang L, Liu Y, Zhang Q. Intrathecal dexmedetomidine as an adjuvant to spinal anesthesia in cesarean section. J Clin Anesth. 2023;83:110842.
[6] Zhang Q, Yang X, Liu Y, Wang H, Li J, Chen L. Intrathecal dexmedetomidine combined with spinal anesthetic for cesarean section: A randomized double-blind study. Front Med (Lausanne). 2022;9:922611.
[7] Ahmed SA, Ismail EA, Elkhateeb RS, Mohamed AA, Hassan ME, Ali RM. Dexmedetomidine versus dexamethasone as intrathecal adjuvants in cesarean section. J Obstet Anaesth Crit Care. 2024;14(1):10–18.
[8] Sultan P, Sharawi N, Blake L, Habib AS, Carvalho B, Landau R. Intrathecal opioids and maternal recovery after cesarean delivery. Int J Obstet Anesth. 2023;55:103627.
[9] Dinesh CN, Sai Teja P, Suresh K, Reddy MS, Prasad A, Rao RM. Comparative evaluation of intrathecal adjuvants in spinal anesthesia for cesarean section. Indian J Anaesth. 2022;66(8):593–599.
[10] Pan PM, Carvalho B, Sultan P, Habib AS, Landau R, Smiley RM. Postoperative analgesia after cesarean delivery: Current evidence. Anesthesiology. 2023;139(3):403–420.
[11] Bajwa SJS, Kaur J, Singh A, Parmar SS, Singh G, Kulshrestha A. Dexmedetomidine and clonidine as spinal adjuvants: A comparative evaluation. Saudi J Anaesth. 2019;13(3):190–197.
[12] Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK. A comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to bupivacaine. J Anaesthesiol Clin Pharmacol. 2011;27(3):339–343.
[13] Sultan P, Gutierrez MC, Carvalho B. Neuraxial morphine and postoperative outcomes after cesarean delivery. Anesth Analg. 2019;129(1):150–158.
[14] Kanazi GE, Aouad MT, Jabbour-Khoury SI, Al Jazzar MD, Alameddine MM, Al-Yaman R. Effect of low-dose dexmedetomidine on spinal block characteristics. Anesth Analg. 2006;103(4):948–953.
[15] El-Shafei MM, Mahfouz AK, Mohamed SA, Farag E, Abd-Elrahman AM, Soliman R. Intrathecal dexmedetomidine in cesarean section: Maternal and neonatal effects. Egypt J Anaesth. 2020;36(1):15–21.